Dyspepsia is a common symptom in general practitioner. Using non invasive serological biomarkers would help to identify individuals at increased risk of atrophic gastritis and gastric cancer. In present study, the evaluation of the utility of a serological gastric panel test combining pepsinogen I (PGI), pepsinogen II (PGII), pepsinogenI/ pepsinogenII ratio (I/II), gastrin-17 (G-17) (basal and stimulated) and Helicobacter pylori (HP) IgG antibodies as a screening method and to predict the state of gastric mucosa: non atrophic, atrophic gastritis and its sequel of developing gastric carcinoma and intestinal metaplasia.
Prediction of gastric mucosa using non invasive immunological blood tests from dyspeptic patients.
PATIENTS AND METHODS:
The serological gastro panel test was evaluated in (54) Iraqi dyspeptic patients divided into two groups: (HP +) and (HP-). Levels of PGI, PGII, PGI/PGII ratio, G-17 basal and stimulated and HP IgG antibodies were determined through a specific immunological non invasive Enzyme Linked Immuno Sorbent Assay (ELISA) test from Biohit PIC, Helsinki, Finland. Using fasting and postprandial samples from those patients.
60% of dyspeptic patients complain from epigastric pain and 62.96% of them had HP +.There were significant increase in PGI, PGII (p<0.05) in NAG .In case of I/II ratio, there was no significant difference between two groups of HP+ and HP-.The other parameter was done is basal G-17 which is significantly increased in HP+ (p>0.05) and postprandial G-17 showed no significant difference between two groups.
Most of those Iraqi dyspeptic patients had non atrophic gastritis due to Helicobacter pylori infection that leads to increased in the PGI, PGII, G-17 through many mechanisms. If HP not treated properly this may leads to atrophic gastritis , peptic ulcer and gastric carcinoma. Gastric panel test was considered as a non endoscope immunological blood test in the diagnosis of atrophic gastritis and its outcome in dyspeptic patients.